Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 26 Publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NILUVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETTNW1KSzVyPUCuNFAxODVzMzFOwG0> M{PQRXNCVkeHUh?=
NCI-H1703 NETjRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnaVYxKSzVyPUCuNFAxQTB{IN88US=> NV7kTFlFW0GQR1XS
KASUMI-1 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEC2PFIh|ryP NXXm[YI3W0GQR1XS
CGTH-W-1 M2C1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\BTWM2OD1yLkCwO|IzKM7:TR?= NUG5dXVDW0GQR1XS
A204 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:1cnNKSzVyPUCuNFA6QTJizszN MmfkV2FPT0WU
HOP-62 NGD1eVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMUC4N|Yh|ryP NIXoeXBUSU6JRWK=
H-EMC-SS NHv5T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTFeW1KSzVyPUCuNVExODVizszN Mn[zV2FPT0WU
KU812 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTBZlRlUUN3ME2wMlE3PTd5IN88US=> MWjTRW5ITVJ?
EM-2 NX;MSXR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkeyTWM2OD1yLkG2PFE3KM7:TR?= NWfQOXIyW0GQR1XS
LAMA-84 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjjfVg1UUN3ME2wMlE4PjZ3IN88US=> NYX0[3d4W0GQR1XS
JAR NFKyO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vQb2lEPTB;MD6yN|k5QSEQvF2= NXvKdpR5W0GQR1XS
G-361 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnmTWM2OD1yLkOyN|I2KM7:TR?= Ml3YV2FPT0WU
KG-1 M3TZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K5e2lEPTB;MD6zO|Y1OiEQvF2= NI\CVFBUSU6JRWK=
BV-173 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHtTWM2OD1yLkO5N|Ih|ryP M4PLeXNCVkeHUh?=
K5 M2PvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq5RWtGUUN3ME2wMlQzOTJ5IN88US=> M3XUNnNCVkeHUh?=
MEG-01 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi0e|hKSzVyPUCuOFI{PjFizszN M1PxXnNCVkeHUh?=
MFM-223 NXHlNZJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwNES3O|Yh|ryP MXvTRW5ITVJ?
BE-13 MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPRXmpKSzVyPUCuOVExODhizszN NVH1cHhrW0GQR1XS
NEC8 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjITWM2OD1yLkeyNVE{KM7:TR?= MoLSV2FPT0WU
SW756 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrDOYVQUUN3ME2wMlk6QDR4IN88US=> NH7McW5USU6JRWK=
A2780 NGX6O5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPETHdKSzVyPUGuNFEyPDZizszN NYKzSllpW0GQR1XS
NB14 NH3KdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDJPW57UUN3ME2xMlAyQDBzIN88US=> MlvLV2FPT0WU
H4 M3;zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyxNYhKSzVyPUGuNFY1OjJizszN NYDEcFV2W0GQR1XS
SK-OV-3 MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DQZ2lEPTB;MT6wOlY{OyEQvF2= MlLtV2FPT0WU
AN3-CA MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i5V2lEPTB;MT6wPFM5QSEQvF2= M2P4[XNCVkeHUh?=
A427 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwMUCzPFEh|ryP MnvCV2FPT0WU
ES7 NYrUOo5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDjTWM2OD1zLkGxN|M1KM7:TR?= M1HJU3NCVkeHUh?=
AGS NFLxRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX4VYhKSzVyPUGuNVE{QTVizszN NVjZU5l{W0GQR1XS
G-402 M1Xhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L6dmlEPTB;MT6xOFY6PCEQvF2= MUTTRW5ITVJ?
ES5 NVn5NZI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwMUeyOFgh|ryP M37ocHNCVkeHUh?=
DEL MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwMkW0OVch|ryP MlWyV2FPT0WU
NB10 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPiUXdkUUN3ME2xMlMzPTV5IN88US=> NYHiR2FQW0GQR1XS
NCI-H1581 NV\SVXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlizTWM2OD1zLkO5NFQzKM7:TR?= MXPTRW5ITVJ?
D-566MG M1Picmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC4NZVOUUN3ME2xMlQxPjh|IN88US=> MmSwV2FPT0WU
LXF-289 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnueW5KSzVyPUGuOFM6QTZizszN NVfvdIVwW0GQR1XS
BT-549 NF7WRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFwNU[5NFkh|ryP M1myO3NCVkeHUh?=
NKM-1 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\DTlEzUUN3ME2xMlYxPTV4IN88US=> NELxUYZUSU6JRWK=
SW780 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;pW5N4UUN3ME2xMlY2OTV6IN88US=> MkXaV2FPT0WU
NCI-H292 NYLQbIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7RTXhQUUN3ME2xMlY3Ozh|IN88US=> MVPTRW5ITVJ?
HMV-II M17LVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPNTWM2OD1zLkewOFg5KM7:TR?= MVzTRW5ITVJ?
ALL-PO MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwOECwNVUh|ryP MWXTRW5ITVJ?
UACC-257 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jCdmlEPTB;MT64NlE3OyEQvF2= MkTzV2FPT0WU
PA-1 NWXSe3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzVPG9IUUN3ME2xMlgzPzJ3IN88US=> NXrhZ3VFW0GQR1XS
HD-MY-Z NXT6R5lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XITGlEPTB;MT64OlI5OSEQvF2= MoPaV2FPT0WU
HSC-4 M2XDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwOUO4N|kh|ryP M3fpe3NCVkeHUh?=
GCT NHzGRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O5U2lEPTB;Mj6wNFkyPiEQvF2= M2PhTnNCVkeHUh?=
RT-112 NV\zUVB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3DcplKSzVyPUKuNVM1OjRizszN MUfTRW5ITVJ?
A172 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfaU|JDUUN3ME2yMlE{PjB4IN88US=> NHLRWJBUSU6JRWK=
HCE-T NVz3bm04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDMfJNKSzVyPUKuNlA2QThizszN MlfuV2FPT0WU
YH-13 NEny[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi1TWM2OD1{LkKxOlcyKM7:TR?= NYnnU3lWW0GQR1XS
DK-MG MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2POU2lEPTB;Mj6yN|g{PCEQvF2= NVPzV2l5W0GQR1XS
ACN NFX2XWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fDOmlEPTB;Mj6yN|g4PSEQvF2= MkLFV2FPT0WU
VA-ES-BJ M3XNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GyVGlEPTB;Mj6yOFk2PyEQvF2= MXzTRW5ITVJ?
L-363 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nYb2lEPTB;Mj6yPFA3OSEQvF2= NUjrcpdLW0GQR1XS
HuH-7 NH\x[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjMeZRKSzVyPUKuOFIyPjVizszN M3TNOXNCVkeHUh?=
A4-Fuk NEfoe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULIS5NYUUN3ME2yMlQ4OTZ6IN88US=> Mo\zV2FPT0WU
T-24 NIXidGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrnUYhzUUN3ME2yMlQ5ODN5IN88US=> MX\TRW5ITVJ?
GOTO NF3oTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfjSYlKSzVyPUKuOVMxOTNizszN MY\TRW5ITVJ?
MV-4-11 M4DKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwNUmxOlkh|ryP MVfTRW5ITVJ?
DMS-114 M1PoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzUUYZ6UUN3ME2yMlY3OzR3IN88US=> M1;lXnNCVkeHUh?=
MHH-NB-11 NFW4S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTK[2N1UUN3ME2yMlcxOjl7IN88US=> NVXJdI85W0GQR1XS
CHP-212 NEfGVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7pbmlyUUN3ME2yMlgzODlzIN88US=> NIn2fpBUSU6JRWK=
DMS-273 NUnTRW1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{npfWlEPTB;Mj65NFIxPyEQvF2= MXfTRW5ITVJ?
SF295 Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P0dmlEPTB;Mz6wNlU6PyEQvF2= NFvZVmtUSU6JRWK=
NCI-H1563 NXi1ZoJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrLdpB3UUN3ME2zMlE2ODB3IN88US=> MonGV2FPT0WU
NCI-H446 NHnxNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHsTWM2OD1|LkKyPFA2KM7:TR?= Mof2V2FPT0WU
HCC1806 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn3VXhbUUN3ME2zMlI4PjV5IN88US=> M3PXWnNCVkeHUh?=
SF126 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTNwM{CwNVch|ryP MWDTRW5ITVJ?
SW982 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDENFRKSzVyPUOuN|M5PzVizszN NXfnOW1xW0GQR1XS
ES8 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTTTWM2OD1|LkO0PVk6KM7:TR?= NUn4bYFJW0GQR1XS
SCC-4 NH7Rb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfCTWM2OD1|LkWwN|k3KM7:TR?= NGnxRZlUSU6JRWK=
RPMI-8226 NX\YfYVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W0XGlEPTB;Mz62NlYyPiEQvF2= NYfMU|NCW0GQR1XS
EW-11 NFrGXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzXTWM2OD1|Lk[zNFIzKM7:TR?= NHPMdZBUSU6JRWK=
COR-L105 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\CbXExUUN3ME2zMlY{OzN2IN88US=> NF3zWmlUSU6JRWK=
ES1 M3\acWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq3TWM2OD1|LkizNFk1KM7:TR?= NVTnfpZDW0GQR1XS
KMOE-2 NW\ldlJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPvWW5KSzVyPUOuPVE5ODhizszN NV;TZXdHW0GQR1XS
ABC-1 M1LWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTSTWM2OD1|LkmzPVEyKM7:TR?= MUDTRW5ITVJ?
NCI-H526 M1TUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwOUmxNlYh|ryP MYHTRW5ITVJ?
HCC1395 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2POXWlEPTB;Mz65PVQ5PCEQvF2= NXe5[Wh7W0GQR1XS
DU-145 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwMUK4NlUh|ryP Ml3pV2FPT0WU
JEG-3 NH3YR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRwMUW5NVYh|ryP Ml;xV2FPT0WU
HCC1187 NWLtSVBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSwTWM2OD12LkKxOVk4KM7:TR?= NYDmV2VoW0GQR1XS
LC-2-ad NYDoT4hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTRwMkKxO|ch|ryP MmjtV2FPT0WU
ONS-76 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H4S2lEPTB;ND6yOFE6OiEQvF2= MkL1V2FPT0WU
CAL-27 NXPaVoljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwMkSzOFQh|ryP NHzYWGZUSU6JRWK=
8-MG-BA NHnqXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLjXpl6UUN3ME20MlI3PjV6IN88US=> M2jPc3NCVkeHUh?=
HGC-27 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfsTWM2OD12LkK5OlYh|ryP NEe1V3RUSU6JRWK=
Hs-578-T MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTRwM{G0Olgh|ryP Ml;CV2FPT0WU
EW-1 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[wOXBKSzVyPUSuOVMxOTRizszN MVHTRW5ITVJ?
SW1573 NE\MSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrJTWM2OD12LkW1NVY{KM7:TR?= MlXGV2FPT0WU
SNU-423 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vQOmlEPTB;ND62NFc6KM7:TR?= M2HLfXNCVkeHUh?=
HOS MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTRwNkm3O{DPxE1? MkLPV2FPT0WU
LB1047-RCC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3UXYJKSzVyPUSuPFE1OThizszN NV7Lb2RmW0GQR1XS
ChaGo-K-1 M1TJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOyTo1EUUN3ME20Mlg6ODR6IN88US=> M3LxZXNCVkeHUh?=
A3-KAW NXjvU29oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXhUXNHUUN3ME20Mlk4OzV{IN88US=> MX\TRW5ITVJ?
CAS-1 NGPtUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTRwOUm5NFgh|ryP MYjTRW5ITVJ?
NBsusSR Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTVwMEO1NVQh|ryP NFLnfoxUSU6JRWK=
KM12 MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTVwMkm4Nlch|ryP NWLvcYk1W0GQR1XS
NCI-H1155 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WwPGlEPTB;NT6zPFE5PSEQvF2= MWrTRW5ITVJ?
EFM-19 NF[4c5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fpOWlEPTB;NT60NVc{PyEQvF2= NYOwOlJ[W0GQR1XS
D-392MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTVwNUe4OFkh|ryP NHHmc2lUSU6JRWK=
JVM-3 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofMTWM2OD13LkeyN|I2KM7:TR?= NFr0R|hUSU6JRWK=
EW-16 NEn5e5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVwN{W1PFMh|ryP M3i5bnNCVkeHUh?=
KARPAS-45 NEi1W5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj3TFh{UUN3ME21Mlg1OzJ3IN88US=> MlrSV2FPT0WU
NCI-H28 NYnke24yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTVwOEe5NVgh|ryP NXLNe2pQW0GQR1XS
COLO-829 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:yTWM2OD13LkmxOVA1KM7:TR?= M1KzdHNCVkeHUh?=
KM-H2 NUPQcHQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfXbldsUUN3ME21MlkzOzl3IN88US=> M3;QcnNCVkeHUh?=
NCI-H82 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrEd3dKSzVyPUWuPVI4PzFizszN NYPz[GdxW0GQR1XS
OAW-42 NU\lboxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITTWZVKSzVyPUWuPVg5OjFizszN MYnTRW5ITVJ?
A704 M1nySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\xTplKSzVyPU[uNVA2PzRizszN M4q0dnNCVkeHUh?=
NCI-H1048 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG4TWM2OD14LkGwOVk6KM7:TR?= Mn\nV2FPT0WU
LOXIMVI NY\HXpRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\LTWM2OD14LkGxNlQ5KM7:TR?= NW\YUFVDW0GQR1XS
MKN45 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LNTWlEPTB;Nj6yOlAyPiEQvF2= M13R[3NCVkeHUh?=
D-502MG M13IRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W2[WlEPTB;Nj6yPFg2PyEQvF2= NWTSbI9GW0GQR1XS
HUTU-80 NHXpZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnjdIZGUUN3ME22MlQyPjh6IN88US=> M{HsZnNCVkeHUh?=
S-117 MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;EUnZDUUN3ME22MlUxOjZ5IN88US=> M1:1WnNCVkeHUh?=
HCC1569 M1LFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzmTWM2OD14LkWzO|M4KM7:TR?= MXLTRW5ITVJ?
J-RT3-T3-5 NIDobZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTZwNUS1O|Ih|ryP NFv4OItUSU6JRWK=
OC-314 M1PiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe2ZlZKSzVyPU[uPVEyPTlizszN MVvTRW5ITVJ?
SNU-449 NGSxe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D5U2lEPTB;Nz6wNVA4OiEQvF2= NI\ae2FUSU6JRWK=
NCI-H720 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnYV4RKSzVyPUeuNVk{PDVizszN Mor6V2FPT0WU
KP-N-YS Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe4TWM2OD15LkKwO|Ih|ryP M2XIe3NCVkeHUh?=
IGROV-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTlfmFOUUN3ME23MlMzOzh4IN88US=> M2DWVHNCVkeHUh?=
SK-PN-DW NXmyO4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\IN5h7UUN3ME23MlQ5OTVizszN MUfTRW5ITVJ?
HCC1419 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3JSlZGUUN3ME23MlU{KM7:TR?= MkLLV2FPT0WU
HAL-01 NXX6e|IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPRfopKSzVyPUeuOlA3PDRizszN MnjZV2FPT0WU
HCC2998 NIHpSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTdwNkC3OFMh|ryP MYrTRW5ITVJ?
SK-N-FI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvhUlBKSzVyPUeuOlMxOzNizszN MYjTRW5ITVJ?
GI-ME-N NYH5ZXJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPPboFKSzVyPUeuOlQ6OzRizszN MVrTRW5ITVJ?
SW1088 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7ob3lKSzVyPUeuOlU5OjZizszN M2fHWHNCVkeHUh?=
IA-LM M3vzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTdwNki2NVMh|ryP NHrrVIRUSU6JRWK=
SK-NEP-1 NWLtbWlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIflZmNKSzVyPUeuOlk3OSEQvF2= MlrSV2FPT0WU
MDA-MB-415 NInObnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DZVmlEPTB;Nz64PVE5PiEQvF2= NYi5OG1oW0GQR1XS
COLO-800 NITmdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DwRmlEPTB;Nz65OFQ6OiEQvF2= MXnTRW5ITVJ?
NCI-H2228 NVz1TGVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTq[m1HUUN3ME24MlE2Pzh|IN88US=> NHHsfZFUSU6JRWK=
D-423MG NF7IXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjIR2JQUUN3ME24MlIyPzJizszN M13pXXNCVkeHUh?=
TE-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K0NGlEPTB;OD60OFMyPiEQvF2= NUfaSmpbW0GQR1XS
NOS-1 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRThwNUG1N|Qh|ryP MoTyV2FPT0WU
8505C NXjXfZB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32ycGlEPTB;OD62OFgzPCEQvF2= M{f3dXNCVkeHUh?=
HEC-1 NGf3em9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvETWM2OD16Lke4OFM6KM7:TR?= NIf5WJlUSU6JRWK=
TE-11 M1r1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v4eWlEPTB;OD65PVU2OSEQvF2= NEPs[3hUSU6JRWK=
CTB-1 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlwMEG0N|Mh|ryP M{LSbXNCVkeHUh?=
TGBC11TKB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHM[IgzUUN3ME25MlAzOjRzIN88US=> MnjSV2FPT0WU
NB17 M3SxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXoTWM2OD17LkG4PFch|ryP M2rnPHNCVkeHUh?=
Becker M{XTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfJU4FCUUN3ME25MlQyQTR2IN88US=> NHfHenFUSU6JRWK=
SN12C NF20UIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnENHZOUUN3ME25MlQ2OjN2IN88US=> MYnTRW5ITVJ?
COLO-320-HSR NFy5O5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33jRmlEPTB;OT62NFI{PyEQvF2= NGq4e5hUSU6JRWK=
D-283MED NWX4[JAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELNbWFKSzVyPUmuOlMxPzJizszN NHPBNYlUSU6JRWK=
D-263MG NYP6Tog1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nN[mlEPTB;OT64N|M5PCEQvF2= NFXXTmJUSU6JRWK=
MEL-JUSO Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17McmlEPTB;OT65NFEzPyEQvF2= MUPTRW5ITVJ?
T98G MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTlwOUCyNFMh|ryP NEjPV2lUSU6JRWK=
HLE MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe3Wo0{UUN3ME25MlkxQTB7IN88US=> Mme1V2FPT0WU
Ca9-22 M{j0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPLZ|BzUUN3ME2xNE4xPjZ3IN88US=> NFTvdJVUSU6JRWK=
OS-RC-2 M3;OTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFyLkGwOFUh|ryP MVrTRW5ITVJ?
T47D NVG4d|VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33pWWlEPTB;MUCuNVU2KM7:TR?= NGTPbWhUSU6JRWK=
GI-1 NYrEZotMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFyLkO1N|Mh|ryP MWDTRW5ITVJ?
NUGC-3 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLoTYxKSzVyPUGwMlQ1ODJizszN NFuzRnRUSU6JRWK=
MDA-MB-361 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj2TWM2OD1zMD60OFMzKM7:TR?= MX\TRW5ITVJ?
SCC-15 NFXBTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;HeGlEPTB;MUCuOFcyQCEQvF2= NEjNVWxUSU6JRWK=
KS-1 NXnhU2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFyLk[zNFEh|ryP M{jMbHNCVkeHUh?=
CAL-12T M4LDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfaTWM2OD1zMD62N|YyKM7:TR?= MlTzV2FPT0WU
OVCAR-4 NYXhW4lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfFNo9KSzVyPUGwMlcxPjhizszN NUHaTYRWW0GQR1XS
HuP-T4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFzLkCzNlgh|ryP MULTRW5ITVJ?
NCI-H358 NUHKOGxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzYc3NUUUN3ME2xNU4zPjV5IN88US=> M{fFWnNCVkeHUh?=
HO-1-N-1 M4S0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SyTmlEPTB;MUGuN|M6QCEQvF2= M4HOR3NCVkeHUh?=
NH-12 M4rrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD1zMT61N|c5KM7:TR?= Mn[1V2FPT0WU
MOLT-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTGbG1OUUN3ME2xNU42QTh3IN88US=> MVTTRW5ITVJ?
K-562 NI\nbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\BfJFKSzVyPUGxMlczPDhizszN Mk\jV2FPT0WU
ES6 NH\lc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLsbHlIUUN3ME2xNU45PThzIN88US=> NETub5ZUSU6JRWK=
RO82-W-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf3THNKSzVyPUGxMlkxPjRizszN NVGyZoFPW0GQR1XS
Ramos-2G6-4C10 M4jYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnncWpKSzVyPUGxMlk{OiEQvF2= NX6zUJVZW0GQR1XS
23132-87 NYXCbXBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TRXWlEPTB;MUKuNFgzOSEQvF2= NHWzWoJUSU6JRWK=
A549 M2LUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnMe4hKSzVyPUGyMlMzQDVizszN MoTaV2FPT0WU
NCI-H23 NXHzdVZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPTNIZMUUN3ME2xNk42ODJ4IN88US=> MoHNV2FPT0WU
H9 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7tTWM2OD1zMj61OVc4KM7:TR?= NEnVe|ZUSU6JRWK=
LB771-HNC M{fHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXMbJRKSzVyPUGyMlc3PSEQvF2= M1vrfnNCVkeHUh?=
QIMR-WIL MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF{LkiyOVgh|ryP MV;TRW5ITVJ?
HSC-3 NX7nSYROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPhd3llUUN3ME2xNk46Ojd4IN88US=> NWXiUph3W0GQR1XS
PFSK-1 M2riS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXoPZdZUUN3ME2xNk46PTB5IN88US=> MkPhV2FPT0WU
ETK-1 M2DxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF|LkC3O|kh|ryP NXLyXHZ1W0GQR1XS
SW1710 NYXTcngyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrPVFJKSzVyPUGzMlM3PDFizszN MkD3V2FPT0WU
COLO-684 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojSTWM2OD1zMz60OVQyKM7:TR?= NYDYbpl7W0GQR1XS
RPMI-7951 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPLcXdGUUN3ME2xN{42OTN4IN88US=> M{PoRnNCVkeHUh?=
A101D NGHpfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DsUmlEPTB;MUOuOVM1QSEQvF2= MUfTRW5ITVJ?
KE-37 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF|LkW4PFch|ryP MVLTRW5ITVJ?
SiHa MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF|LkizOFYh|ryP NHXtNnZUSU6JRWK=
NCI-H226 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjoTW12UUN3ME2xN{45QDB6IN88US=> NYCxSYJ1W0GQR1XS
DB MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke2TWM2OD1zMz65PVI5KM7:TR?= M3\SUnNCVkeHUh?=
HT-1197 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTRTWM2OD1zND6wPFA6KM7:TR?= NY\YWHpFW0GQR1XS
SBC-5 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3BTWM2OD1zND6xN|YzKM7:TR?= NET2PIdUSU6JRWK=
VMRC-RCZ NYjBV4ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF2LkW3O|Qh|ryP Moq1V2FPT0WU
697 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;ZXnhKSzVyPUG0MlYzPyEQvF2= NVPO[nd1W0GQR1XS
OMC-1 NFPHfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm1cWtoUUN3ME2xOE44QDh6IN88US=> M1TCeHNCVkeHUh?=
SKG-IIIa NG\2UYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7FTWM2OD1zND64NFAyKM7:TR?= NYOwd2RjW0GQR1XS
DOK MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPpTWM2OD1zND65PVM{KM7:TR?= MVLTRW5ITVJ?
NCI-H2029 NFr3cGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\n[49KSzVyPUG1MlM3ODJizszN MYLTRW5ITVJ?
NCI-H2009 NGPnV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rsXmlEPTB;MUWuOVA6PSEQvF2= MVTTRW5ITVJ?
LK-2 M1n5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL2TWM2OD1zNT62OFQ6KM7:TR?= MYPTRW5ITVJ?
NCI-H661 NVLQZmh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm3NIJVUUN3ME2xOU46ODd3IN88US=> M3LHZ3NCVkeHUh?=
GT3TKB Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nlcGlEPTB;MU[uNFY4PiEQvF2= M2\BT3NCVkeHUh?=
GP5d MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPJe3BKSzVyPUG2MlM1OiEQvF2= NFLEU45USU6JRWK=
SK-MEL-2 NXP0fHVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF4LkS0PFUh|ryP MVXTRW5ITVJ?
SK-UT-1 NUPFbFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0VWZKSzVyPUG2MlU3PSEQvF2= M1e1SHNCVkeHUh?=
NB7 M1XEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnflTWM2OD1zNj62PVcyKM7:TR?= NIrkR5ZUSU6JRWK=
NCI-H460 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF4LkezNlYh|ryP NILVdY1USU6JRWK=
8305C MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILpZXhKSzVyPUG2Mlc5PzdizszN NILsPWlUSU6JRWK=
CaR-1 M4PzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF4LkixNVEh|ryP NEPQVnJUSU6JRWK=
D-247MG NXy0dJNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnQS3BEUUN3ME2xOk45PjJ3IN88US=> MULTRW5ITVJ?
LoVo NIjHSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\aWpVDUUN3ME2xOk46PDh6IN88US=> MmDtV2FPT0WU
NCI-H2405 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDrUVJKSzVyPUG3MlE6ODhizszN MVXTRW5ITVJ?
AU565 M4PkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInqNGxKSzVyPUG3MlIzPSEQvF2= M4PJbnNCVkeHUh?=
OCI-AML2 Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF5LkWzNVch|ryP NXXFZ5pWW0GQR1XS
22RV1 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK1TWM2OD1zNz61PFg1KM7:TR?= MWjTRW5ITVJ?
HT-144 NXHHd|RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjCfoJKSzVyPUG3MlY2QThizszN NFS5SJRUSU6JRWK=
HuO9 M4\DOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\aTWM2OD1zNz63NFMyKM7:TR?= NFy3botUSU6JRWK=
Daoy M2X0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TxZ2lEPTB;MUeuO|E5PCEQvF2= M3LXe3NCVkeHUh?=
SJRH30 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3Id2VxUUN3ME2xO{45PDh7IN88US=> MVLTRW5ITVJ?
CHL-1 M{nSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjuT4lPUUN3ME2xO{46OjR7IN88US=> Mnr0V2FPT0WU
J82 M2HJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF5Lkm2N|Uh|ryP NEL4WohUSU6JRWK=
COR-L23 NIn2SnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zTWM2OD1zOD6wNFEyKM7:TR?= NV3HfYVSW0GQR1XS
SNU-C2B NHrkfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKzNG5KSzVyPUG4MlIzPzZizszN MVjTRW5ITVJ?
NCI-H1770 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjYTJFKSzVyPUG4MlQ3OTVizszN MXPTRW5ITVJ?
MHH-PREB-1 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF6LkW2PVch|ryP MV\TRW5ITVJ?
ES3 M3;kWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF6LkW4PFMh|ryP NV7TbXNMW0GQR1XS
MDA-MB-231 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF6Lk[1NFIh|ryP NYj2XpRwW0GQR1XS
MN-60 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF7LkC1PVIh|ryP M3vMPHNCVkeHUh?=
EPLC-272H MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOx[G0{UUN3ME2xPU4{PzB6IN88US=> MWTTRW5ITVJ?
SW948 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF7LkO5N|Qh|ryP MY\TRW5ITVJ?
MOLT-13 NYD4dIZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF7LkS1OFYh|ryP NEnnS5hUSU6JRWK=
HL-60 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;ScFV[UUN3ME2yNE4zOTRzIN88US=> Mn\ZV2FPT0WU
CP50-MEL-B NWXzWYpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXWOpVKSzVyPUKwMlQ4PDhizszN MVXTRW5ITVJ?
NTERA-S-cl-D1 M2HWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJyLkS5O|gh|ryP MUHTRW5ITVJ?
KINGS-1 MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjkNnR{UUN3ME2yNE44QTZ5IN88US=> NFjNO2RUSU6JRWK=
DOHH-2 NUnwOFZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJyLkmwOkDPxE1? MoDMV2FPT0WU
BB65-RCC NGmxT|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7heGNKSzVyPUKwMlkzQDVizszN MX7TRW5ITVJ?
NB12 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XWTWlEPTB;MkGuNFM6PCEQvF2= NX3ubYdyW0GQR1XS
KY821 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jqNWlEPTB;MkGuOVgzKM7:TR?= MXvTRW5ITVJ?
PSN1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfrOWtKSzVyPUKxMlY1PTNizszN MmDPV2FPT0WU
EGI-1 M1Tqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJzLke0OVQh|ryP NWP2V5ZkW0GQR1XS
CTV-1 NYrKS2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ{LkOwN|Eh|ryP MnX4V2FPT0WU
TI-73 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTzTWM2OD1{Mj6zOFk5KM7:TR?= NEPBbYlUSU6JRWK=
LCLC-103H MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ{LkS3OVIh|ryP NIK0WVJUSU6JRWK=
D-542MG MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELIUpJKSzVyPUKyMlU2PThizszN NEXNeYJUSU6JRWK=
ATN-1 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XS[WlEPTB;MkKuOlQ{QSEQvF2= NELwWnFUSU6JRWK=
SK-MEL-1 NHXjR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnKTWM2OD1{Mj64N|Y5KM7:TR?= NGPGV5JUSU6JRWK=
HDLM-2 NGDBeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7vTWM2OD1{Mz6xOFc5KM7:TR?= M4fXbXNCVkeHUh?=
UM-UC-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTQTWM2OD1{Mz6xPVQ1KM7:TR?= NF;Jc29USU6JRWK=
NCI-H1573 M3jW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ|LkS2PFEh|ryP MYLTRW5ITVJ?
NCI-H520 NETweWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLZN3dKSzVyPUKzMlQ6PDhizszN MlLNV2FPT0WU
ESS-1 NWXJWIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7LRmVKSzVyPUKzMlgxPTlizszN NET6WIVUSU6JRWK=
COR-L88 NXfBdlAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ|Lkm0O|Uh|ryP MX\TRW5ITVJ?
TGBC24TKB NVTFWXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ2LkCzNVIh|ryP MlXTV2FPT0WU
HCC1937 NHzNUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\TfpB4UUN3ME2yOE4yKM7:TR?= NVXjcHFHW0GQR1XS
RS4-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHXbo52UUN3ME2yOE4yPDJizszN NWnI[4d4W0GQR1XS
HCC38 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnmfI9KSzVyPUK0MlI{QTRizszN NGmzW5BUSU6JRWK=
RPMI-2650 M2XFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJ2Lk[xOlIh|ryP M4P0SnNCVkeHUh?=
P12-ICHIKAWA M2nV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HNVWlEPTB;MkSuOlI2QCEQvF2= M{ixT3NCVkeHUh?=
YAPC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ2LkiyNVQh|ryP MmnEV2FPT0WU
NB13 NGXId4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPDZ4RKSzVyPUK1MlI3OTFizszN M3nKWHNCVkeHUh?=
SK-N-AS M3vtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rabmlEPTB;MkWuPFU5PCEQvF2= MXfTRW5ITVJ?
SK-N-DZ MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NViyNG9oUUN3ME2yOk4xPDlizszN MnPaV2FPT0WU
LS-411N NITnUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDtTWM2OD1{Nj6yNFM5KM7:TR?= MWPTRW5ITVJ?
NCI-H810 NY\1S4FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\aTWM2OD1{Nj6zNVEzKM7:TR?= MYfTRW5ITVJ?
NCI-SNU-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fSUGlEPTB;Mk[uOVQ2PCEQvF2= NGGxNGtUSU6JRWK=
HH MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PvSGlEPTB;Mk[uOVUzQSEQvF2= M2rmXXNCVkeHUh?=
U-2-OS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\YTWM2OD1{Nj63N|gzKM7:TR?= MnroV2FPT0WU
SF539 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ4LkiwNVgh|ryP MWnTRW5ITVJ?
NCI-H2052 NIDtXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny0TWM2OD1{Nz6wPFYh|ryP NITMWWZUSU6JRWK=
A673 M4\ac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f3cGlEPTB;MkeuNlExOiEQvF2= MX7TRW5ITVJ?
WM-115 NWqxNlFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zrTWlEPTB;MkeuO|c3PyEQvF2= MlryV2FPT0WU
SW48 M4rteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ5LkiwNFUh|ryP MWnTRW5ITVJ?
NOMO-1 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ5Lki1N|Ih|ryP MV\TRW5ITVJ?
PC-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKyTWM2OD1{Nz64PVQyKM7:TR?= NX;rR5dmW0GQR1XS
UMC-11 NIryUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rtbmlEPTB;MkeuPVM1OyEQvF2= NVXYW|VxW0GQR1XS
U-118-MG M4XIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPYRYlKSzVyPUK4MlAyOjNizszN Mn7nV2FPT0WU
NCI-H2452 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJ6LkC4NlIh|ryP MWPTRW5ITVJ?
CAMA-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPzNJFKSzVyPUK4Mlg2PjRizszN MUHTRW5ITVJ?
MC-IXC NX3HcIllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fzemlEPTB;MkmuNlM3PiEQvF2= NVruVJdHW0GQR1XS
ES4 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ7LkOxO|Ih|ryP Mk\WV2FPT0WU
BHT-101 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PreWlEPTB;MkmuN|IyKM7:TR?= NIfXSWpUSU6JRWK=
KP-4 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjBcGxKSzVyPUK5MlUyPiEQvF2= MXTTRW5ITVJ?
CAL-54 M4PPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fZfGlEPTB;MkmuOVQ1PSEQvF2= MWPTRW5ITVJ?
5637 M3\KO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfEc5pKSzVyPUK5MlY1OjFizszN MXzTRW5ITVJ?
MOLT-16 M1XjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ7LkeyOlkh|ryP NYS0NZU4W0GQR1XS
Ca-Ski MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHLSoVKSzVyPUK5Mlk1PiEQvF2= M{Du[nNCVkeHUh?=
AsPC-1 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITMUJFKSzVyPUOwMlAzOTJizszN MUXTRW5ITVJ?
MSTO-211H NH3lXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;uTWM2OD1|MD6xOUDPxE1? NWLF[|JkW0GQR1XS
L-428 M1nafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L3RmlEPTB;M{CuOFA2KM7:TR?= M{PEVnNCVkeHUh?=
SW1463 NVnBNWlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjmbmxKSzVyPUOwMlU{QDNizszN NWS1Wo5IW0GQR1XS
NCI-H1648 NIHDWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG1cIVXUUN3ME2zNE42PTd2IN88US=> MkLQV2FPT0WU
CAKI-1 NX;iOI42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nKRWlEPTB;M{CuO|cxOiEQvF2= M{TTT3NCVkeHUh?=
YKG-1 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Kwd2lEPTB;M{GuNFI3OyEQvF2= NGfCd3ZUSU6JRWK=
A2058 NXLGNJFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNzLkGxOlQh|ryP NGTVNpVUSU6JRWK=
A375 M4XYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULxOWNNUUN3ME2zNU4yPjl4IN88US=> NVHYUmdWW0GQR1XS
SNB75 M3ryOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;jNmlEPTB;M{GuNlQ{PSEQvF2= NEDGZ29USU6JRWK=
SK-HEP-1 M33EO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j3VmlEPTB;M{GuOFI4OSEQvF2= Ml25V2FPT0WU
ME-180 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonuTWM2OD1|MT62OVQzKM7:TR?= NHi3bFRUSU6JRWK=
NCI-H209 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLRTWM2OD1|MT64NlQ4KM7:TR?= MUDTRW5ITVJ?
HC-1 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj5TWM2OD1|Mj6xOFQ3KM7:TR?= Mnq4V2FPT0WU
LB373-MEL-D NF7JT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPXXZRKSzVyPUOyMlE6PzFizszN M3;qeXNCVkeHUh?=
SNU-387 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\JTWM2OD1|Mj6zNVkyKM7:TR?= NHf2WYpUSU6JRWK=
C32 M3fV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf3TWM2OD1|Mj6zN|U{KM7:TR?= NVjWSG1jW0GQR1XS
EW-13 NVO0WYFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTN{Lkm0NFgh|ryP MWHTRW5ITVJ?
BFTC-905 M1m0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX3TWM2OD1|Mz61NVM3KM7:TR?= NX3IUVQ6W0GQR1XS
NCI-H1299 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;PflhuUUN3ME2zN{42PjJzIN88US=> M{X1S3NCVkeHUh?=
LU-135 NWPTU4tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PxdmlEPTB;M{OuPFAyKM7:TR?= MVPTRW5ITVJ?
NCI-H2122 NFjiem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP1TWM2OD1|Mz65PVY3KM7:TR?= M4nQ[HNCVkeHUh?=
SK-LMS-1 Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH2epd4UUN3ME2zOE41OTB5IN88US=> Mn3tV2FPT0WU
LNCaP-Clone-FGC NI\h[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN2Lki1NVUh|ryP NWn3bGtOW0GQR1XS
NCI-H1092 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv0N3IyUUN3ME2zOU4zPzR5IN88US=> MYjTRW5ITVJ?
MS-1 M1XYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTN3LkOwN|gh|ryP MYTTRW5ITVJ?
KYSE-510 NHPCNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN3LkWwOFIh|ryP M2fqfnNCVkeHUh?=
NCI-H1793 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDURmcyUUN3ME2zOU43PTR3IN88US=> MWfTRW5ITVJ?
MIA-PaCa-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXiTWM2OD1|Nj6wOFk3KM7:TR?= NF3yNZhUSU6JRWK=
EW-22 NFjpWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHRTWM2OD1|Nj60NFczKM7:TR?= MmP2V2FPT0WU
IGR-1 NID5Z2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3BTWM2OD1|Nj64NVg1KM7:TR?= M4fISHNCVkeHUh?=
HT-1080 NWjoW3RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLzblk1UUN3ME2zO{4yOjVizszN M1\nbnNCVkeHUh?=
M14 NXLtcYx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzsN5NSUUN3ME2zO{4yPjR{IN88US=> NXTZUo5VW0GQR1XS
786-0 NYfGS|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW3W2lKSzVyPUO3MlI4QTRizszN NX\vTHcyW0GQR1XS
MZ2-MEL Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TrZ2lEPTB;M{euOFUxOSEQvF2= MYrTRW5ITVJ?
NCI-H510A MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHxTWM2OD1|Nz65OFEzKM7:TR?= NXjURnpsW0GQR1XS
LAN-6 NXL4OodzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jzWGlEPTB;M{euPVU5OiEQvF2= MWTTRW5ITVJ?
SW620 M1\XVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnkTWM2OD1|OD60PVc1KM7:TR?= MmHaV2FPT0WU
LB2241-RCC Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XBPGlEPTB;M{muPFIxPSEQvF2= M4frPHNCVkeHUh?=
Detroit562 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn6bppRUUN3ME20NE4yOjZ6IN88US=> NEfLdJNUSU6JRWK=
HN NX60SoZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfMZYFIUUN3ME20NE4yPzh{IN88US=> MljaV2FPT0WU
HCT-15 MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzsV4xKUUN3ME20NE42QTB5IN88US=> M{T2RXNCVkeHUh?=
C2BBe1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrTdIgxUUN3ME20NE46OTV5IN88US=> MnLoV2FPT0WU
A498 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTwVXNzUUN3ME20NU4{ODF3IN88US=> NHHzNHZUSU6JRWK=
SK-MEL-24 M4fHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLKTWM2OD12MT60O|I2KM7:TR?= NWDCPJJDW0GQR1XS
OVCAR-5 M1i0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\oWI1KSzVyPUSxMlc4PjdizszN M{j6U3NCVkeHUh?=
NCI-H1792 NIXuc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j2V2lEPTB;NEGuPVgzOSEQvF2= MmPDV2FPT0WU
KOSC-2 M{izOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXiPVF6UUN3ME20Nk4zPjl7IN88US=> MkXZV2FPT0WU
Mo-T M4\2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qxZWlEPTB;NEKuPFk2QCEQvF2= NGO5bopUSU6JRWK=
CFPAC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXTT3hHUUN3ME20N{41QTR2IN88US=> NU\NVms5W0GQR1XS
CAL-51 NH3VbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj6SI1KSzVyPUSzMlU3ODVizszN MVXTRW5ITVJ?
RH-18 NXzN[pJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTR|LkiwOUDPxE1? Mk\tV2FPT0WU
EC-GI-10 NGTjU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTR|LkizOFch|ryP M4rFRXNCVkeHUh?=
HSC-2 NVvYXWZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHOXXpKSzVyPUS0MlAxQSEQvF2= NUPN[|J6W0GQR1XS
ML-2 NETpTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnLRo9KUUN3ME20OU4zPjJzIN88US=> MWXTRW5ITVJ?
KNS-81-FD M3HwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe2bVVJUUN3ME20OU44OzZ3IN88US=> NH\ufWVUSU6JRWK=
NB6 NFTZVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTR4LkGxNUDPxE1? M4HpWXNCVkeHUh?=
MCF7 MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR4LkW1N|Mh|ryP MWXTRW5ITVJ?
P30-OHK M4nPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHTO41KSzVyPUS2MlgyOTdizszN M3XNTnNCVkeHUh?=
BPH-1 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki5TWM2OD12Nj65PFA2KM7:TR?= NWjBOmVSW0GQR1XS
U251 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonhTWM2OD12Nj65PVQh|ryP NHToe3FUSU6JRWK=
MKN1 M3j2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyyTpRjUUN3ME20O{42OTN5IN88US=> NXjn[48yW0GQR1XS
A431 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ETWM2OD12Nz64N|M5KM7:TR?= MVrTRW5ITVJ?
C8166 NHn3dJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z5TWlEPTB;NEmuNlA{QSEQvF2= NEXCOWJUSU6JRWK=
HEL NVvid4N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDUWnByUUN3ME20PU41ODZ2IN88US=> NIfqTHFUSU6JRWK=
RMG-I M4jjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuwT49KSzVyPUS5MlQ1PDRizszN MkGwV2FPT0WU
CAL-72 NInNZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR7Lk[wO|Uh|ryP Mn3aV2FPT0WU
SW962 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR7LkmzN|Ih|ryP MmT5V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; 

PubMed: 31205508     


Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines.

PARP / cleaved PARP / caspase-3 / cleaved caspase-3; 

PubMed: 31205508     


Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.

31205508
Immunofluorescence
alpha-tubulin; 

PubMed: 26474283     


Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM

26474283
Growth inhibition assay
Cell viability ; 

PubMed: 26474283     


A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€

26474283
In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03826589 Not yet recruiting Cervical Cancer The University of Hong Kong June 1 2019 Not Applicable
NCT03826589 Not yet recruiting Cervical Cancer The University of Hong Kong June 1 2019 Not Applicable
NCT03839498 Recruiting Pheochromocytoma|Paraganglioma Columbia University|Pfizer January 22 2019 Phase 2
NCT03839498 Recruiting Pheochromocytoma|Paraganglioma Columbia University|Pfizer January 22 2019 Phase 2
NCT03595124 Recruiting Metastatic Renal Cell Carcinoma|Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|TFE3 Gene Translocation|TFEB Gene Translocation National Cancer Institute (NCI) October 9 2018 Phase 2
NCT03595124 Recruiting Metastatic Renal Cell Carcinoma|Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|TFE3 Gene Translocation|TFEB Gene Translocation National Cancer Institute (NCI) October 9 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products4

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID